Yang Yan-Hui, Xing Zhe-Hua, Wang Hao, Zhang Chi, Liu Yu-Bo, Bai Qian-Qian, Liu Fang-Fei, Liu Wei-Feng, Yang Jun-Chuan, Li Da-Huan, Fan Hua
Department of Emergency Medicine, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technolog, Luoyang, Henan, China.
Front Oncol. 2025 Mar 20;15:1555649. doi: 10.3389/fonc.2025.1555649. eCollection 2025.
The ubiquitin proteasome system is involved in the regulation of cellular gene transcription and cellular receptor function through the degradation of proteins, thus affecting tumorigenesis and development. In this study, bioinformatics analysis revealed the expression of PSMD11 and PSMD14 in pancreatic ductal adenocarcinoma, which can be used as biomarkers for the prognosis of patients with PDAC. This study provides new targets for the prognostic assessment and targeted therapy of pancreatic ductal adenocarcinoma.
The expression levels and prognostic value of PSMD11 and PSMD14 in pancreatic ductal adenocarcinoma patients were analyzed using the GEPIA2, GEO, TCGA and GTEx databases, and the relationships between these expression levels and clinical case data and the survival and prognosis of patients with pancreatic ductal adenocarcinoma were analyzed. The effects of PSMD11 and PSMD14 on the malignant biological behaviors of pancreatic cancer cells, such as proliferation, migration and invasion, were investigated by experiments.
Bioinformatics analysis revealed that the expression levels of PSMD11 and PSMD14 mRNAs were significantly higher in pancreatic ductal adenocarcinoma (PDAC) tissues than in normal pancreatic tissues and that this high expression was correlated with a poor prognosis in patients with PDAC. Further evaluation of the expression of PSMD11 and PSMD14 and correlation of the results with the clinical characteristics and survival of patients with PDAC revealed that high expression of PSMD11 and PSMD14 was associated with lymph node metastasis, TNM grade, degree of differentiation, and poor prognosis in patients with PDAC. Knockdown of PSMD11 and PSMD14 significantly inhibited the proliferation, migration, and invasion ability of pancreatic cancer cells.
PSMD11 and PSMD14 are highly expressed in pancreatic ductal adenocarcinoma tissues and are correlated with the degree of malignancy of pancreatic ductal adenocarcinoma; thus, PSMD11 and PSMD14 can be used as potential prognostic biomarkers and therapeutic targets for PDAC patients.
泛素蛋白酶体系统通过蛋白质降解参与细胞基因转录和细胞受体功能的调节，从而影响肿瘤的发生和发展。在本研究中，生物信息学分析揭示了PSMD11和PSMD14在胰腺导管腺癌中的表达情况，其可作为胰腺导管腺癌患者预后的生物标志物。本研究为胰腺导管腺癌的预后评估和靶向治疗提供了新的靶点。
利用GEPIA2、GEO、TCGA和GTEx数据库分析胰腺导管腺癌患者中PSMD11和PSMD14的表达水平及预后价值，并分析这些表达水平与临床病例数据以及胰腺导管腺癌患者生存和预后之间的关系。通过实验研究PSMD11和PSMD14对胰腺癌细胞恶性生物学行为（如增殖、迁移和侵袭）的影响。
生物信息学分析显示，胰腺导管腺癌（PDAC）组织中PSMD11和PSMD14 mRNA的表达水平显著高于正常胰腺组织，且这种高表达与PDAC患者的不良预后相关。对PSMD11和PSMD14的表达及结果与PDAC患者临床特征和生存的相关性进行进一步评估发现，PSMD11和PSMD14的高表达与PDAC患者的淋巴结转移、TNM分级、分化程度及不良预后相关。敲低PSMD11和PSMD14可显著抑制胰腺癌细胞的增殖、迁移和侵袭能力。
PSMD11和PSMD14在胰腺导管腺癌组织中高表达，且与胰腺导管腺癌的恶性程度相关；因此，PSMD11和PSMD14可作为PDAC患者潜在的预后生物标志物和治疗靶点。
